Key Highlights
- Argenica Therapeutics(ASX:AGN) disclosed the FDA has maintained the clinical hold on its xaranetide IND for acute ischaemic stroke
- The FDA requested a GLP non-clinical neurotoxicity study to assess whether xaranetide forms Olney lesions in rats
- The FDA also revised downward the permitted clinical exposure limit, below the doses in Argenica's proposed Phase 2b trial design
- Argenica plans to request a Type A meeting with the FDA while continuing regulatory submissions in other jurisdictions
Argenica Therapeutics Limited(ASX:AGN) announced on 19 November 2026 that the United States Food and Drug Administration (FDA) has completed its review of the company's clinical hold complete response and has advised that removal of the clinical hold is not warranted at this time.
The Perth-based biotechnology company submitted a complete response on 23 September 2026 addressing matters raised in the FDA's August 2025 letter. The FDA's feedback maintaining the hold was provided over four weeks after the mandatory 30-day deadline.
What Has the FDA Requested?
The FDA has requested two principal items to be addressed. First, an additional GLP non-clinical neurotoxicity study to assess whether xaranetide forms toxic Olney lesions in rats. Olney lesions can form in rats given high-affinity NMDA channel blockers that produce sustained, complete receptor blockade. The FDA has requested this study be completed before commencement of clinical dosing in the US. No microscopic damage to the brain has been identified in non-clinical animal studies of xaranetide conducted to date.
Second, the FDA has revised downward the permitted clinical exposure limit, derived from non-GLP toxicokinetic data in a single rat cohort. The revised limit sits below the doses in Argenica's proposed Phase 2b trial design, meaning any future US study would need to commence at a lower dose with a dose escalation plan. Argenica stated it does not agree with this view and has identified issues with the data on which the decision was based.
What Is the Scientific Context?
Recent mechanism-of-action studies show that xaranetide is a non-competitive, voltage-dependent, partial NMDA receptor inhibitor. The company notes that xaranetide is not a complete NMDA receptor blocker, is reversible, and is not administered chronically in stroke, which it considers distinguishes it from the class of compounds typically associated with Olney lesion formation.
Argenica will seek quotes from clinical research organisations to determine the Investment required for the neurotoxicity study. The FDA has offered to review the study protocol in advance.
Regarding the clinical exposure limit, the company stated that a preliminary review identified substantially greater variability in the data being relied upon by the FDA, and that the revised limit does not align with previously provided GLP toxicokinetic data. The company plans to work with its nonclinical contract research organisation to verify the variability.
What Are the Next Steps?
Argenica plans to request a Type A meeting to discuss the matters further with the FDA. The company stated it will continue to progress regulatory submissions in other jurisdictions while the US situation is addressed.
The company maintains conviction in xaranetide's potential based on preclinical efficacy studies and the signal shown in severe stroke patients in the Phase 2 trial.
Where Does Argenica Stand Going Forward?
The continued clinical hold means US clinical development of xaranetide will be delayed while the additional non-clinical study is conducted and the exposure limit issue is resolved. The parallel pursuit of approvals in other jurisdictions provides an alternative pathway for clinical advancement.






Please wait processing your request...